20 mg in female arousal studies Subcutaneous injection: 0.75 mg, 1.25 mg, and 1.75 mg in Phase 2-3 female HSDD trials FDA-approved dose: 1.75 mg subcutaneously as needed, at least 45 minutes before sexual activity Important: These are doses from completed clinical trials
Table 1 comprehensively discusses previous literature and compares it with our paper
Treating a thickened uterine lining during postmenopausal bleeding Treatment for a thickened uterine lining depends entirely on whether atypical cells are present
Common side effects of SEMALIX 7 TABLET may include nausea, abdominal discomfort, diarrhoea, reduced appetite, vomiting, constipation, heartburn, altered taste, tiredness, dizziness, and increased pancreatic enzymes such as lipase and amylase
Perfetti R, Zhou J, Doyle ME, Egan JM
PlexusDx patients receive guidance on injection schedules, nutrition timing, and realistic activity targets to maximize results alongside medication